DAPK2 Downregulation Associates With Attenuated Adipocyte Autophagic Clearance in Human Obesity

Hedi Soussi1, Sophie Reggio1, Rohia Alili1

  • 1Nutriomics Team, INSERM, UMR_S U1166, Paris, France Université Pierre et Marie Curie, Sorbonne Universités, UMR_S 1166, Paris, France Institute of Cardiometabolism and Nutrition, Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Paris, France.

Diabetes
|June 4, 2015
PubMed

Insights

Death-associated protein kinase 2 (DAPK2) is downregulated in obesity, impairing autophagy in fat cells. Restoring DAPK2 may improve autophagic clearance and reduce lipid accumulation in obesity.

Area of Science:

  • Metabolic research
  • Cell biology
  • Obesity research

Background:

  • Adipose tissue dysfunction in obesity is linked to inflammation and insulin resistance.
  • Death-associated protein kinase 2 (DAPK2) is downregulated in human obesity adipose tissue.
  • The role of DAPK2 in adipocytes and obesity remains unclear.

Purpose of the Study:

  • To investigate the role of DAPK2 in adipocyte function and autophagy.
  • To determine the impact of DAPK2 on autophagic clearance in obesity.
  • To assess DAPK2 expression and autophagic flux in obese patients and after weight loss.

Main Methods:

  • DAPK2 expression analysis in human adipose tissue and mice.
  • Adenoviral-mediated DAPK2 overexpression in 3T3-L1 adipocytes.
  • Small interfering RNA (siRNA) mediated DAPK2 inhibition in human preadipocytes.
  • Assessment of autophagic flux using LC3-II accumulation.
  • Analysis of adipocyte autophagic clearance in obese patients before and after bariatric surgery.

Main Results:

  • DAPK2 is primarily expressed in mature adipocytes and downregulated in obesity.
  • DAPK2 overexpression enhances autophagic clearance in adipocytes.
  • DAPK2 inhibition impairs autophagic flux.
  • Obese adipocytes exhibit reduced autophagic flux, inversely correlated with fat cell lipid content.
  • Bariatric surgery-induced weight loss partially restores adipocyte autophagic clearance.

Conclusions:

  • Adipocyte DAPK2 expression regulates lysosome-mediated clearance and lipid accumulation.
  • Obesity is associated with attenuated autophagy in adipocytes.
  • DAPK2 plays a crucial role in regulating adipocyte autophagy, suggesting it as a potential therapeutic target for obesity-related metabolic dysfunction.

Related Concept Videos

cAMP-dependent Protein Kinase Pathways01:25

cAMP-dependent Protein Kinase Pathways

Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
9.3K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.4K
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
303
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
404
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR...
3.0K